<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299295</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL023</org_study_id>
    <nct_id>NCT04299295</nct_id>
  </id_info>
  <brief_title>To Evaluate the Performance and Safety of YVOIRE Y Solution 360 Versus Comparator for Lips and Perioral Area.</brief_title>
  <official_title>A Study to Evaluate the Performance and Safety of YVOIRE Y-Solution 360 Versus Comparator for Temporary Enhancement and Pouting of the Lips for Lip Augmentation and Correction of Perioral Area.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Performance and Safety of YVOIRE Y-Solution 360 on Lips and Perioral
      Area.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Study
      to Evaluate the Performance and Safety of YVOIRE Y-Solution 360 Versus Comparator for
      Temporary Enhancement and Pouting of the Lips for Lip Augmentation and Correction of Perioral
      Area
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">February 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change on the overall Lip Fullness Rating Scale (LFRS) from baseline to Week12.</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 on overall Lip 12 weeks after treatment, the mean change from baseline to 12 weeks will be measured using 5-point Lip Fullness Rating Scale (LFRS). LFRS Grades are 0 (None/Minimal), 1 (Mild), 2 (Moderate), 3 (Pronounced), and 4 (Very Pronounced).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate calculated using Lip Fullness Rating Scale (LFRS) for overall lip at Week12.</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 on overall Lip 12 weeks after treatment, the responder rate defined as ≥ 1-point improvement on the 5-point Lip Fullness Rating Scale (LFRS) from baseline to 12 weeks will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change on Lip Fullness Rating Scale (LFRS) from baseline to Week2, 4, 12 and 24.</measure>
    <time_frame>2, 4, 12, 24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 at 2, 4, 12, and 24 weeks after treatment, the mean change from baseline to at 2, 4, 12, and 24 weeks will be measured using 5-point Lip Fullness Rating Scale (LFRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate on Lip Fullness Rating Scale (LFRS) from baseline to Week2, 4, 12 and 24.</measure>
    <time_frame>2, 4, 12, 24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 at 2, 4, 12, and 24 weeks after treatment, the responder rate (defined as at a least 1-point improvement) from baseline to at 2, 4, 12, and 24 weeks will be measured using 5-point Lip Fullness Rating Scale (LFRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change on Vertical Perioral Lip lines Rating Scale - At rest(VPLRS) from baseline to Week2, 4, 12 and 24.</measure>
    <time_frame>2, 4, 12, 24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 on perioral area at 2, 4, 12, and 24 weeks after treatment, the mean change from baseline to at 2, 4, 12, and 24 weeks will be measured using 5-point Vertical Perioral Lip lines Rating Scale - At rest (VPLRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate on Vertical Perioral Lip lines Rating Scale - At rest(VPLRS) from baseline to Week2, 4, 12 and 24.</measure>
    <time_frame>2, 4, 12, 24 weeks from baseline</time_frame>
    <description>To evaluate the performance of YVOIRE Y-Solution 360 on perioral area at 2, 4, 12, and 24 weeks after treatment, the responder rate (as at a least 1-point improvement) from baseline to at 2, 4, 12, and 24 weeks will be measured using 5-point Vertical Perioral Lip lines Rating Scale - At rest (VPLRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) evaluation by subject and investigator.</measure>
    <time_frame>2, 4, 12, 24 weeks from baseline</time_frame>
    <description>To measure the satisfaction of YVOIRE Y-Solution 360 the GAIS evaluation will be performed by subject and investigator. GAIS Grade are -2 (Much Worse), -1 (Worse), 0 (No change), 1 (Improved), and 2 (Much improved).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Lip Augmentation</condition>
  <arm_group>
    <arm_group_label>YVOIRE Y-Solution 360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid dermal filler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Juvéderm VOLBELLA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyaluronic acid dermal filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE Y-Solution 360</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>YVOIRE Y-Solution 360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvéderm VOLBELLA</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>Juvéderm VOLBELLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years or above age.

          -  1 or 2 of the 5-point (0-4) LFRS (Lip Fullness Rating Scale).

          -  Agree to use proper contraception as guided in the protocol.

          -  Signed for Informed Consent.

        Exclusion Criteria:

          -  have lip tattoos, piercings, facial hair, or scars that would interfere with
             visualization of the lips and perioral area

          -  who have dentures or any device covering all or part of the upper palate, and/or
             severe malocclusion or dentofacial or maxillofacial deformities

          -  have undergone oral surgery within 6 weeks

          -  have received permanent facial implants in the face or neck, or are planning to be
             implanted with any of these products

          -  have undergone semi-permanent filler in lower face within 24 months

          -  have undergone temporary dermal filler treatment in the lower face within 12 months

          -  Have undergone facial tissue augmentation or facial treatment with fat or botulinum
             injections in the lower face within 6 months

          -  Have undergone mesotherapy, face lift, laser, photo modulation, intense pulsed light,
             radio frequency, dermabrasion, moderate or greater depth chemical peel, or other
             ablative procedures in face or neck within 6 months

          -  have used lip plumping products within 10 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja C. Fischer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haut-und Lasercentrum Potsdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Yeop Shin</last_name>
    <phone>+82-2-6987-4147</phone>
    <email>dongyeopshin@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haut-und Lasercentrum Potsdam</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja C. Fisher</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

